Catalog No.
Product Name
Application
Product Information
Citations
-
PDE11A Modulator
PDE11A modulator-1 is a selective modulator targeting phosphodiesterase 11A (PDE11A). This compound enhances intracellular cAMP levels, thereby influencing various signaling pathways. It has potential applications in the study of metabolic disorders and neurological conditions linked to cAMP signaling. PDE11A modulator-1 serves as a valuable tool for researchers investigating the role of PDE11A in cellular processes and therapeutic development. -
PDE IV Inhibitor
RS14203 is a potent inhibitor of phosphodiesterase type IV (PDE IV), which plays a crucial role in the regulation of cyclic nucleotide signaling. This compound is known to induce emesis, making it valuable in research focused on gastrointestinal function and the emetic response. Its application extends to investigations of PDE IV's involvement in various physiological processes and the development of therapeutic strategies targeting cyclic nucleotide pathways. -
PDE2 Inhibitor
BML-288 is a potent inhibitor of phosphodiesterase 2 (PDE2) with an IC50 value of 40 nM. This compound demonstrates significant biological activity in modulating cyclic nucleotide levels, making it relevant for research into osteoarthritis pain and related conditions. Its ability to selectively inhibit PDE2 provides valuable insights into cellular signaling pathways and therapeutic targets in inflammatory and pain-related disorders. -
Phosphodiesterase (PDE)
Oxagrelate is a selective inhibitor of cyclic adenosine monophosphate phosphodiesterase (PDE). It demonstrates concentration-dependent inhibition of platelet aggregation induced by collagen and adenosine diphosphate (ADP) in vitro. This compound is valuable for research applications focused on platelet activation, hemostasis, and thrombotic disorders. -
PDE5 Inhibitor
UK-371800 is a highly selective phosphodiesterase 5 (PDE5) inhibitor, exhibiting an IC50 of 4.2 nM. This compound demonstrates favorable permeability characteristics and remains unaffected by P-glycoprotein efflux mechanisms. UK-371800 is primarily utilized in research applications related to erectile dysfunction and pulmonary hypertension, contributing to the understanding of cGMP signaling pathways in cardiovascular health. -
PDE Inhibitor
PDE-IN-3 is a phosphodiesterase (PDE) inhibitor exhibiting an IC50 value of 260 μM. This compound effectively modulates the breakdown of cyclic nucleotides, making it a valuable tool for investigating intracellular signaling pathways. PDE-IN-3 is applicable in research areas such as cardiovascular biology, neurobiology, and cancer research, where PDE inhibitors play a critical role in therapeutic strategies. -
PDE5 Inhibitor
UK 357903 is a selective inhibitor of phosphodiesterase 5 (PDE5), exhibiting IC50 values of 1.7 nM for PDE5 and 714 nM for PDE6. This compound demonstrates significant vasodilatory effects in mesenteric and hindlimb vascular beds, making it a promising candidate for research applications related to erectile dysfunction and vascular smooth muscle relaxation. Its mechanism of action provides a valuable tool for investigating PDE5-related pathways in various physiological and pathological contexts. -
PDE4 Inhibitor
PDE4-IN-25 is a potent phosphodiesterase 4 (PDE4) inhibitor, exhibiting an IC50 value of 0.1 μM. This compound is significant in the study of inflammatory diseases, as it regulates intracellular cyclic nucleotide levels, thereby influencing inflammatory response pathways. PDE4-IN-25 is valuable for researchers investigating therapeutic interventions for conditions characterized by dysregulated inflammation. -
PDE4 Inhibitor
LEO 29102 is a potent inhibitor of phosphodiesterase 4 (PDE4) with an IC50 value of 5 nM. This compound effectively inhibits the release of TNFα, making it a valuable tool for studies related to inflammatory responses. LEO 29102 shows promise in the research of atopic dermatitis and other related conditions associated with PDE4 activity. -
Cyclic AMP-PDE Inhibitor
2'-O-MB-cGMP sodium is a cyclic GMP-specific phosphodiesterase inhibitor with an I50 value of 35 µM. It effectively inhibits the hydrolysis of cyclic nucleotides by Ca2+-dependent phosphodiesterases, utilizing cAMP or cGMP as substrates. This compound is invaluable in research focused on cyclic nucleotide signaling pathways and can aid in the study of vascular smooth muscle function, platelet aggregation, and a range of physiological processes influenced by cyclic GMP. -
PDE5 Inhibitor
T-0156 free base is a selective inhibitor of phosphodiesterase type 5 (PDE5), functioning through competitive inhibition of cyclic guanosine monophosphate (cGMP) hydrolysis, with an IC50 of 0.23 nM. In addition to its primary target, T-0156 exhibits some inhibitory activity against PDE6 with an IC50 of 56 nM, while demonstrating low potency against other PDEs, including PDE1, PDE2, PDE3, and PDE4 (IC50 > 10 μM). This compound plays a valuable role in enhancing the nitric oxide (NO)/cGMP signaling pathway, making it suitable for research in vascular biology and therapies related to erectile dysfunction and pulmonary hypertension. -
PDE Inhibitor
Irsogladine maleate is a phosphodiesterase 4 (PDE4) inhibitor that enhances intracellular cyclic adenosine monophosphate (cAMP) levels. This compound exhibits anti-inflammatory properties and is primarily utilized in research focused on chronic inflammatory diseases and gastric protection mechanisms. Additionally, its affinity for muscarinic acetylcholine receptors may provide insights into neuroprotective effects and gastrointestinal motility studies. -
PDE III Inhibitor
Adibendan (BM 14478) is a selective phosphodiesterase III (PDE III) inhibitor, exhibiting an IC50 value of 2.0 μM. With over 60-fold selectivity compared to PDE I and II inhibitors, Adibendan functions as a novel cardiotonic agent. This compound is valuable for researchers investigating cardiovascular diseases and exploring the modulation of cardiac contractility through PDE III inhibition. -
PDE10A Inhibitor
Mardepodect precursor is the chemical precursor of Mardepodect, a selective inhibitor targeting phosphodiesterase 10A (PDE10A). This compound exhibits potent inhibitory activity with an IC50 of 0.37 nM and displays greater than 1000-fold selectivity over other phosphodiesterases. Mardepodect and its precursor are integral for research into neuropsychiatric disorders, promoting the understanding of PDE10A's role in central nervous system functions. -
PDE Inhibitor
LY 186126 is a potent phosphodiesterase (PDE) inhibitor that acts by targeting cardiac sarcoplasmic reticulum PDE with a high binding affinity (Kd = 5.6 nM). This compound is utilized in research related to cardiac function and signaling pathways by modulating cyclic nucleotide levels, making it valuable for studies on cardiovascular conditions and PDE-related mechanisms. -
PDE Inhibitor
Quazodine is a potent phosphodiesterase (PDE) inhibitor that modulates intracellular cAMP and cGMP levels. Its primary activity involves vasodilatory effects, making it a valuable tool in studies related to vascular smooth muscle function. Quazodine is suitable for research applications exploring cardiovascular diseases and smooth muscle physiology. -
Phosphodiesterase (PDE) Inhibitor
K-252d is an indolocarbazole alkaloid that acts primarily as a phosphodiesterase (PDE) inhibitor. It demonstrates significant inhibitory activity against calcium- and calmodulin-dependent phosphodiesterase isolated from bovine heart, with an IC50 of 46.2 μM, and is also recognized for its role as a protein kinase C (PKC) inhibitor, exhibiting an IC50 of 350 nM against PKC isolated from rat brain. This compound is valuable for studies related to signal transduction pathways and therapeutic interventions targeting PDE-related disorders. -
PDE Stabilizer
6-Cl-cPuMP sodium is a cAMP analog that acts as a phosphodiesterase (PDE) stabilizer. This compound exhibits excellent membrane permeability, allowing for effective cellular uptake, while maintaining stability against PDE degradation. 6-Cl-cPuMP sodium is particularly useful in research related to the nervous system, enabling studies of cAMP signaling pathways and their implications in neurobiology. -
PDE4 Inhibitor
Cipamfylline is a potent inhibitor of phosphodiesterase 4 (PDE4), specifically facilitating the accumulation of PDE4A4 within distinct cellular regions via its interaction with the ubiquitin scaffolding protein p62. This compound plays a critical role in research focused on atopic dermatitis, contributing to the understanding of inflammatory pathways and potential therapeutic interventions in this condition. -
PDE4 Inhibitor
ONO-6126 is a selective phosphodiesterase 4 (PDE4) inhibitor with potential therapeutic applications in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). By inhibiting PDE4, it increases intracellular cAMP levels, which can help reduce inflammation and bronchoconstriction. This compound is valuable for research focused on understanding the molecular mechanisms of respiratory conditions and testing novel therapeutic strategies. -
PDE4 Inhibitor
Braylin is a potent phosphodiesterase-4 (PDE4) inhibitor that plays a significant role in anti-inflammatory and immunomodulatory processes. It is particularly relevant in the exploration of immunoinflammatory diseases, making it a valuable tool for researchers studying these conditions. Its ability to modulate inflammatory responses positions it as a potential therapeutic target in related research applications. -
PDE4 Inhibitor
RS-25344 is a selective inhibitor of phosphodiesterase type IV (PDE4), which plays a crucial role in the degradation of cyclic adenosine monophosphate (cAMP). By inhibiting PDE4 activity, RS-25344 promotes increased intracellular cAMP levels, contributing to an array of biological responses. This compound is valuable for research in inflammation, immune disorders, neurodegenerative diseases, and cardiovascular conditions. Its ability to modulate cAMP signaling makes it a significant tool for exploring therapeutic strategies in these areas. -
PDE5 Inhibitor
Desmethyl thiosildenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. This compound exhibits significant biological activity by promoting vasodilation through the inhibition of PDE5, thereby enhancing nitric oxide signaling. It is commonly used in research applications focused on cardiovascular function and erectile dysfunction, providing insights into the therapeutic potential for related disorders. -
PDE5 Inhibitor
JNJ-10258859 is a highly selective phosphodiesterase type 5 (PDE5) inhibitor, exhibiting a Ki value of 0.23 nM. This compound effectively elevates cyclic GMP levels, which is crucial for promoting smooth muscle relaxation and improving erectile function. JNJ-10258859 is primarily utilized in research focused on erectile dysfunction and related cardiovascular studies. -
PDE2 Agonist
5,6-DM-cBIMP is a cyclic nucleotide analog that serves as an agonist for phosphodiesterase 2 (PDE2). It is capable of significantly enhancing the hydrolytic activities of cAMP and cGMP by PDE2, making it a valuable tool for researchers investigating the modulation of cyclic nucleotide signaling pathways. Its application is particularly relevant in studies focused on cardiovascular and neurological research. -
PDE1 Inhibitor
MMPX is a potent phosphodiesterase type 1 (PDE1) inhibitor that modulates intracellular signaling pathways by increasing cyclic nucleotide levels. This compound exhibits significant biological activity in various cellular processes, making it a valuable tool for studying the physiological roles of PDE1 in neurological and cardiovascular research. Its application extends to exploring therapeutic strategies for diseases associated with dysregulated cyclic nucleotide signaling. -
PDE5 Inhibitor
BMS-341400 mesylate is a selective phosphodiesterase 5 (PDE5) inhibitor, exhibiting an IC50 value of 0.3 nM. This compound attenuates the degradation of cyclic guanosine monophosphate (cGMP), thereby facilitating nitric oxide (NO)-induced relaxation of corpus cavernosum smooth muscle and enhancing erectile function. BMS-341400 mesylate serves as a valuable tool for investigating mechanisms underlying erectile dysfunction. -
KRAS-PDEδ Inhibitor
NHTD is a selective inhibitor of KRAS-PDEδ, targeting the prenyl-binding pocket of PDEδ and modulating the cellular localization of KRAS. This action effectively inhibits the proliferation of KRAS-mutant cancer cells and promotes apoptosis. NHTD is a valuable tool for investigations into KRAS-driven non-small cell lung cancer (NSCLC) and related oncology research. -
Phosphodiesterase (PDE) Inhibitor
Saterinone is a phosphodiesterase III (PDE III) inhibitor that enhances intracellular cAMP levels, leading to increased vasodilation and improved cardiac function. This compound is significant in cardiovascular research, particularly in studies focused on heart failure and angina. Its role in modulating cAMP signaling pathways makes it an important tool for exploring therapeutic strategies in cardiovascular diseases. -
Phosphodiesterase (PDE) Inhibitor
PDE IV-IN-1 is a selective inhibitor of phosphodiesterase IV (PDE4), an enzyme involved in the degradation of cyclic AMP. This compound exhibits anti-inflammatory properties, making it valuable for the research of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), as well as other inflammatory diseases. Its ability to modulate cAMP levels positions PDE IV-IN-1 as a significant tool in the study of inflammatory signaling pathways. -
Phosphodiesterase (PDE) Inhibitor
L791943 is a selective phosphodiesterase-4 (PDE4) inhibitor, demonstrating a potent inhibitory effect with an IC50 value of 4.2 nM. This compound is primarily utilized in research aimed at understanding the role of PDE4 in various inflammatory and neurological disorders. Its efficacy in modulating cyclic nucleotide levels makes it a valuable tool for studying signal transduction pathways and therapeutic interventions. -
Phosphodiesterase (PDE) Inhibitor
Sch59498 is a potent inhibitor of phosphodiesterase 1C (PDE1C), a phosphodiesterase enzyme involved in cellular signal transduction through the hydrolysis of cyclic nucleotides. This compound demonstrates significant effects on intracellular cAMP and cGMP levels, thereby influencing various physiological processes. Sch59498 is primarily utilized in research applications focused on cardiovascular diseases, neuroprotection, and cancer biology, providing insights into the modulation of signaling pathways associated with these conditions. -
Phosphodiesterase (PDE) Inhibitor
Win-62005 is a potent inhibitor of cyclic AMP phosphodiesterase III (PDE III), exhibiting Ki values of 25 nM for rat heart and 26 nM for canine aorta. This compound is primarily utilized in cardiovascular research to explore its effects on cAMP signaling pathways and its potential therapeutic applications in heart conditions. Through the inhibition of PDE III, Win-62005 enhances intracellular cAMP levels, thereby influencing myocardial contractility and vascular tone. -
Cathepsin A Substrate
FA-Phe-Phe is a furylacryloyl (fa)-amino acid derivative that serves as a specific substrate for Cathepsin A. This compound is valuable in elucidating the enzymatic activity and functional mechanisms of Cathepsin A, contributing to research on its role in physiological and pathological processes. FA-Phe-Phe is particularly useful in studies involving enzymatic assays and screening for potential inhibitors or modulators of Cathepsin A. -
PKCα Inhibitor
Leucosceptoside A is a phenylethanoid glycoside that functions as a selective inhibitor of Protein Kinase C alpha (PKCα). This compound demonstrates significant anti-hyperglycemic and anti-hypertensive effects and exhibits inhibitory activity against α-glucosidase, with an IC50 value of 19.0 μM. Leucosceptoside A is relevant for research into metabolic disorders and cardiovascular diseases, providing insights into therapeutic approaches targeting PKCα. -
Ciprofloxacin Prodrug
Ciprofloxacin prodrug-1 is an activated prodrug targeting β-lactamase-producing bacteria. It demonstrates potent antibacterial activity, with a minimum inhibitory concentration (MIC) of 63 nM against β-lactamase-expressing strains. Upon hydrolysis by β-lactamase, Ciprofloxacin prodrug-1 releases the active antibiotic Ciprofloxacin, effectively inhibiting DNA gyrase activity. This compound is valuable for investigating infections caused by drug-resistant bacteria, particularly uropathogenic Escherichia coli. -
CYP1A2 Inhibitor
Frutinone A is a selective inhibitor of CYP1A2, featuring a chromonocoumarin structural scaffold. This compound exhibits notable antibacterial and antioxidant activities, making it a valuable tool for research in pharmacology and toxicology. Its ability to modulate the activity of CYP1A2 underscores its potential for studying drug metabolism and interactions. -
Human Endogenous Metabolite
Estradiol hemihydrate is a steroid hormone primarily involved in female reproductive health. It has been shown to up-regulate the expression of neural markers in human endometrial stem cells, promoting their differentiation into neural lineages. This compound is useful for research in areas such as cancer biology, neurodegenerative diseases, and neural tissue engineering. -
Stable Isotope
Rabeprazole sulfide-d3 is a deuterium-labeled analog of Rabeprazole Sulfide, which serves as a metabolite of the proton pump inhibitor Rabeprazole. This compound effectively inhibits the motility of Helicobacter pylori, making it a valuable tool for studying H. pylori infections. Rabeprazole sulfide-d3 can facilitate research on antibiotic resistance and the mechanisms underlying H. pylori pathogenesis. -
Peptide Sex Pheromone
cCF10 is a peptide sex pheromone that facilitates the transfer of the conjugative plasmid pCF10 from donor to recipient bacterial cells. Its mechanism involves activation of the Opp transport system, allowing cCF10 to enter the cells and inhibit the accumulation of (p)ppGpp, a signaling molecule involved in stress responses. By maintaining a metabolically active state in bacteria, cCF10 effectively reduces the generation of persister cells, making it a valuable tool for research into bacterial conjugation and cell response dynamics. -
α-Glucosidase Inhibitor
CKD-711 is an orally active aminooligosaccharide that functions as a potent inhibitor of α-glucosidase, with an IC50 of 78 μg/mL. It also demonstrates inhibitory effects against porcine intestinal maltase and sucrose, with IC50 values of 2.5 and 0.5 μg/mL, respectively. Additionally, CKD-711 exhibits selective antibacterial activity against Comamonas terrigena. This compound is valuable for research into infections and metabolic disorders, including diabetes. -
CYP3A Inhibitor
Troleandomycin, a macrolide antibiotic, functions as a selective inhibitor of the cytochrome P450 enzyme CYP3A. This compound is primarily used in research to investigate drug metabolism and interactions related to CYP3A. Additionally, it has applications in studies involving corticosteroids for conditions such as asthma, providing insights into therapeutic efficacy and safety profiles. -
Endogenous Metabolite
DL-3-Phenyllactic acid is an endogenous metabolite known for its broad-spectrum antimicrobial activity. It plays a crucial role in cellular metabolism and has potential applications in research related to microbial inhibition and metabolic regulation. This compound is particularly valuable for studying microbial resistance and the modulation of metabolic pathways in various biological systems. -
Endogenous Metabolite
Acetyl phosphate lithium potassium is an endogenous metabolite that serves as a critical regulator in bacterial metabolism. It is particularly significant in the process of lysine acetylation, influencing bacterial responses to environmental stresses and aiding in adaptive mechanisms. This compound is valuable for research involving bacterial metabolic pathways and the study of cellular stress responses. -
Endogenous Metabolite
Maleic acid is an endogenous metabolite that acts as an inhibitor of Glutamate Decarboxylase (GAD) in various bacterial species, including Escherichia coli and Listeria monocytogenes. It is primarily utilized in research applications investigating GAD activity and its implications in metabolic pathways. This compound is valuable for studies focused on microbial metabolism and the modulation of related biochemical processes. -
Semaphorin3A/Phospholipase C/FabI Inhibitor
Vinaxanthone is a selective inhibitor of semaphorin3A, phospholipase C (PLC), and FabI, exhibiting IC50 values of 0.1-0.2 μM for semaphorin3A and 0.9 mM for FabI. This compound also inhibits the substrate t-o-NAC thioester and the cofactor NADPH, with inhibition constants (Kis) of 3.1 μM and 1.0 μM, respectively. Vinaxanthone shows potential for combating infections caused by multidrug-resistant pathogens, making it a valuable tool for research in infectious diseases and drug resistance mechanisms. -
Endogenous Metabolite
Tridecanoic acid, a 13-carbon medium-chain saturated fatty acid, functions as an endogenous metabolite. It exhibits significant antipersister and antibiofilm properties, making it valuable for studies related to bacterial infections. Notably, Tridecanoic acid inhibits persistence and biofilm formation in Escherichia coli, providing a useful tool for research in microbial behavior and infection control. -
Endogenous Metabolite
1-Kestose is an endogenous metabolite categorized as the smallest fructooligosaccharide. It serves as a prebiotic that effectively stimulates the growth of beneficial gut bacteria, particularly Faecalibacterium prausnitzii and various Bifidobacteria. This compound is valuable for research applications focusing on gut microbiota modulation and its associated health benefits. -
SHMT Inhibitor
(Rac)-SHIN2 is a pyrazolopyran derivative that functions as a selective inhibitor of serine hydroxymethyltransferase (SHMT). This compound demonstrates significant antibacterial activity, effectively targeting both vancomycin-susceptible and vanA-type vancomycin-resistant Enterococcus, while exhibiting low cytotoxicity towards Hep2 cells. The potential applications of (Rac)-SHIN2 include investigation into bacterial resistance mechanisms and the development of novel antibacterial therapeutics. -
Endogenous Metabolite
2(5H)-Furanone, also known as γ-Crotonolactone, is an endogenous metabolite that mimics N-acyl homoserine lactone signals, targeting LuxR homologs to disrupt quorum sensing-mediated gene regulation. This compound effectively inhibits quorum sensing associated with AHLs of varying acyl chain lengths and reduces biofilm formation in environmental *Aeromonas hydrophila* strains on polystyrene surfaces. Additionally, 2(5H)-Furanone has been shown to suppress spike-and-wave discharges in rat models of generalized absence seizures, demonstrating selective efficacy against this type of seizure. Its diverse biological activities make it a valuable reagent for research into bacterial infections and seizure disorders.
